Abstract | Introduction: Recombinant neorudin (EPR- hirudin, EH) was developed through the addition of an EPR (Glu- Pro-Arg) peptide to the amino terminus of hirudin, which can be recognized and cut by coagulation factors XIa (FXIa) and/or Xa (FXa). In this study, the low- bleeding antithrombotic effects of EH were evaluated utilizing experimental models of thrombosis in rabbits and rats to provide a test basis for clinical trials. Methods: The bleeding risks of EH and hirudin were first compared in mice by the tail-clipping method, and then the antithrombotic activity of EH was investigated in a rabbit model of arteriovenous bypass thrombosis and a rat model of thrombotic cerebral infarction. Results: Conclusion: The findings from the preclinical animal models used in this study showed that EH could not only effectively inhibit thrombus formation but also reduce the risk of bleeding.
|
Authors | Yu-Bin Liu, Lin Zhang, Xing-Chen Zhou, Ying Zhou, Yun Liu, Can Zheng, Xiao Xu, Pan-Pan Geng, Chun-Hua Hao, Zhuan-You Zhao, Chu-Tse Wu, Ji-De Jin |
Journal | Drug design, development and therapy
(Drug Des Devel Ther)
Vol. 16
Pg. 1667-1678
( 2022)
ISSN: 1177-8881 [Electronic] New Zealand |
PMID | 35677424
(Publication Type: Journal Article)
|
Copyright | © 2022 Liu et al. |
Chemical References |
- Fibrinolytic Agents
- Heparin, Low-Molecular-Weight
- Hirudins
- Recombinant Proteins
- Saline Solution
|
Topics |
- Animals
- Cerebral Infarction
(drug therapy)
- Fibrinolytic Agents
(therapeutic use)
- Hemorrhage
(drug therapy)
- Heparin, Low-Molecular-Weight
(therapeutic use)
- Hirudins
(pharmacology)
- Mice
- Rabbits
- Rats
- Recombinant Proteins
- Saline Solution
- Thrombosis
(drug therapy)
|